Daria Lewis
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 72.2% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $23,580, more than ten times the $1,903 reported in 2021. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,002 payments — averaging $66.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$48K
- Johnson & Johnson$3K
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- plus $7K from 22 others
What the payments were for
- Consulting fees$7,18011%
- Speaking & faculty fees$31,93548%
- Travel & lodging$5,3428%
- Food & beverage$21,75933%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 167 | $47,876 |
| Johnson & Johnson | 91 | $3,007 |
| Otsuka America Pharmaceutical, Inc. | 96 | $2,588 |
| AbbVie | 141 | $2,542 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 124 | $1,872 |
| Neurocrine Biosciences, Inc. | 71 | $1,768 |
| Vanda Pharmaceuticals Inc. | 71 | $1,604 |
| Teva Pharmaceuticals USA, Inc. | 48 | $963 |
| E.r. Squibb & Sons, L.L.C. | 18 | $668 |
| Supernus Pharmaceuticals, Inc. | 35 | $655 |
| Corium, LLC | 32 | $641 |
| Lundbeck LLC | 24 | $561 |
| Indivior Inc. | 17 | $353 |
| Axsome Therapeutics, Inc. | 11 | $291 |
| USWM, LLC | 12 | $223 |
| Sunovion Pharmaceuticals Inc. | 10 | $159 |
| Almatica Pharma LLC | 8 | $131 |
| Orexo US, Inc. | 5 | $77 |
| Eisai Inc. | 4 | $69 |
| Tris Pharma Inc | 3 | $49 |
| Noven Therapeutics, LLC | 3 | $46 |
| Luye Pharma (USA) Ltd. | 2 | $43 |
| Braeburn Inc. | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$175,464
- ARISTADA$2,521
- INVEGA SUSTENNA$1,165
- VRAYLAR$1,021
- CAPLYTA$600
- ARISTADA INITIO$525
- INGREZZA$502
- REXULTI$358
- Fanapt$347
- COBENFY$333
- INVEGA TRINZA$252
- ABILIFY MAINTENA$232
- ABILIFY ASIMTUFII$232
- QELBREE$228
- AUSTEDO$125
- Auvelity$122
- NUEDEXTA$122
- UZEDY$115
- Austedo XR$103
How this compares
$66,345 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 34 | $309,679 |
| LybalviOlanzapine/Samidorphan Malate | 155 | $257,102 |
| VraylarCariprazine Hcl | 161 | $226,439 |
| FanaptIloperidone | 75 | $159,155 |
| Invega SustennaPaliperidone Palmitate | 48 | $138,667 |
| RexultiBrexpiprazole | 65 | $105,739 |
| AristadaAripiprazole Lauroxil | 14 | $50,685 |
| CaplytaLumateperone Tosylate | 25 | $43,651 |
| Abilify MaintenaAripiprazole | 14 | $38,006 |
| Risperdal ConstaRisperidone Microspheres | 24 | $29,666 |
| Aripiprazole | 300 | $16,210 |
| Clozapine | 221 | $13,054 |
| Asenapine Maleate | 74 | $13,046 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 26 | $10,713 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 99 | $10,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $3,007 | $478,012106 claims |
| Alkermes, Inc.Lybalvi, Aristada | $47,876 | $307,787169 claims |
| AbbVieVraylar | $2,542 | $226,439161 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,604 | $159,15575 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,588 | $143,74579 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,872 | $43,65125 claims |
| Orexo US, Inc.Zubsolv | $77 | $10,71326 claims |
| Almatica Pharma LLCLoreev Xr | $131 | $9,41020 claims |
| Eisai Inc.Dayvigo | $69 | $4,06012 claims |
| Indivior Inc.Suboxone | $353 | $3,27911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Cary
- Amanda KellyCary$94K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.